Candel Therapeutics, Inc. (CADL) SEC Filings & Earnings Calls

Clinical trial failure risk

“We may never succeed in obtaining regulatory approval for any of our product candidates.” · word for word

Financing risk

“We will require additional capital to commercialize aglatimagene in early localized prostate cancer, to support enrollment and conduct the phase 3 trial for aglatimagene in NSCLC, and to advance the development of linoserpaturev beyond the current trials.” · word for word

Regulatory approval risk

“We are in ongoing dialogue with the FDA in preparation for the Company’s anticipated submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer in the fourth quarter of 2026.” · word for word

Clinical trial failure risk; no approved products; reliance on BLA approval.

“Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec in localized prostate cancer in Q4 2026.” · word for word

No material risk; standard executive compensation.

“Standard employment terms with severance and change-in-control provisions”

Clinical trial risk; no regulatory approval yet.

“Phase 3 trial data; forward-looking statements about regulatory approval and commercialization”

Clinical-stage company with no approved products; regulatory and commercial execution risks

“BLA submission planned for Q4 2026; no revenue reported”

No approved products or revenue

“To date, we have not generated any revenue from product sales and do not expect to generate any revenue from sales of products in the foreseeable future.” · word for word

Need for additional capital

“We will require additional capital to commercialize aglatimagene in early localized prostate cancer, to advance the phase 3 trial for aglatimagene in NSCLC, and to advance the development of linoserpaturev beyond the current trials.” · word for word

Clinical trial failure risk

“We may never succeed in obtaining regulatory approval for any of our product candidates.” · word for word

Dilution risk from equity financings

“We have raised approximately $385.9 million of gross proceeds from such transactions, including ... $301.6 million from the sale of our common stock and accompanying pre-funded warrants” · word for word

Clinical-stage biotech with no approved products; regulatory and trial risks are significant.

“Clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients fight cancer” · word for word

Dilution risk from equity offering and debt from term loan facility.

“$93.5 million in net proceeds from the February 2026 follow-on equity offering; $130 million term loan facility” · word for word

Clinical trial failure risk

“We may never succeed in obtaining regulatory approval for any of our product candidates.” · word for word

Funding risk

“We believe our existing cash and cash equivalents, together with the net proceeds from the 2026 Follow-On Offering, will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2028.” · word for word

Regulatory approval risk

“The RTW Purchase Agreement is subject to certain closing conditions, including that FDA approval must occur by a specified date.”

Dilution risk from equity offering; potential for further dilution if underwriters exercise option for additional shares.

“Underwriters have 30-day option to purchase up to an additional 2,752,293 shares.”

Royalty financing contingent on FDA approval; if approval delayed or not obtained, no funding received.

“the Purchaser has agreed to pay the Company $100 million upon the marketing approval of CAN-2409.” · word for word

Forward-looking statements highlight risks typical for clinical-stage biotech: trial outcomes, regulatory approval, financing needs.

“Forward-looking statements include risks related to initiation, timing, progress, results, and cost of research and development programs.”

Going concern risk due to continued losses and need for additional funding

“The Company expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future.” · word for word

Dependence on clinical trial success for CAN-2409 and CAN-3110

“Our business is dependent on the success of CAN-2409, CAN-3110 and any other product candidates that we advance into the clinic.” · word for word

Clinical-stage biotech with no approved products; reliance on successful clinical trials and regulatory approvals.

“Clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies.” · word for word

Debt financing adds leverage and interest obligations.

“$130 million term loan facility with Trinity Capital Inc.” · word for word